We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. 
We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

We have four proprietary AI prediction models: PIONEER, ObsERV, EDEN and RAVEN.

National Institutes of Health

Lincoln Park Capital Fund

Evaxion Biotech A/S

IPhone / Mobile Compatible

Viewport Meta

Apple Mobile Web Clips Icon

HSTS

Google Maps

Pound Sterling

jQuery CDN

Next.js

Mobile Optimized

Pexels

Jens Kringelum

Director, Genomic Immuno Oncology

Andreas Holm Mattsson

Chief Innovation Officer and Founder

Thomas Frederik Schmidt

Birgitte Rønø

Chief Scientific Officer & Director of Cancer Vaccines

Niels Moeller

CBO and founder

Per Norlén

Chief Executive Officer

Pär Comstedt

Director, Infectious Disease Vaccines

European Union (EU) Public Companies With Less Than $1B in Revenue

Europe, Middle East, and Africa (EMEA) Public Companies With Less Than $1M in Revenue

Europe, Middle East, and Africa (EMEA) Companies that Exited (Top 10K)

Europe Companies With Fewer Than 1000 Employees (Top 10K)

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.

Merck Global Health Innovation Fund

Post-IPO Equity - Evaxion Biotech

Negma Group

Post-IPO Debt - Evaxion Biotech

Grant - Evaxion Biotech

Venture Round - Evaxion Biotech

Copenhagen

Hovedstaden

Denmark

Europe

Evaxion Biotech

Evaxion Biotech files to sell 5.25M American Depositary Shares

European Equities Traded in the US as American Depositary Rise in Monday Trading

Other news to note for Nov. 15, 2024

Evaxion announces business update and third quarter 2024 financial results

Evaxion Biotech showcases improved performance of EvaxMHC

Evaxion Biotech issues letter with a corporate update

Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now

Evaxion reports positive results for melanoma vaccine

Evaxion Biotech advances in personalized cancer vaccine

Evaxion reports positive results for melanoma vaccine By Investing.com

A personalized cancer vaccine in Phase 2 clinical trial, targeting patient-specific tumor antigens.

A vaccine antigen against Staphylococcus Aureus infection, currently in development.

A platform utilizing artificial intelligence to develop immunotherapies for cancer and infectious diseases.

A model for designing personalized neoantigen vaccines.

A model for designing personalized ERV-antigen vaccines.

A model predicting responses to cancer CPI immunotherapy.

India

Asia

Turkey

Australia

Oceania

The Netherlands

HTML5

Google Analytics

Microsoft Outlook

Wistia

Modernizr

Adobe Fonts

Cloudflare CDN

Wordpress

Facebook Comments

Vimeo

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 7, 2024 12:34 PM	b8d5e3a7
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 12:34 PM	b7e9fdbf
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	f4ff8de8
crunchbase profile	general	Nov 27, 2024 1:23 PM	364dd35f
li profile	general	Feb 1, 2024 4:22 PM	71bd7211
translate crunchbase fundingrounds	general	Nov 27, 2024 3:00 PM	f22f3055
peers	general	Feb 1, 2024 4:22 PM	774fe91e
news basic	general	Mar 7, 2024 12:34 PM	6790acf1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EVAXION-BIOTECH

Evaxion Biotech A/S

Last Close

1.39

22/11 21:00

Market Cap

16.59M

Beta: -

Volume Today

13.33K

Avg: -